SCHEMBL3916446

SCHEMBL3916446

Cc1ccc(S(=O)(=O)Nc2ccc3c(c2)c(=O)[nH]n3CCc2ccccc2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.41
LMNA P02545 2/20 0.41
BRPF1 P55201 1/20 0.41
NR1I2 O75469 6/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PARP1 P09874 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ITGA1 P56199 1/20 0.38
DAO P14920 1/20 0.37
PLK1 P53350 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903013 0.90 NR1I2 (0.39) BRD4LMNANR1I2MAPTKMT2A
SCHEMBL3904770 0.87 NR1I2 (0.43) BRD4LMNANR1I2MAPTKMT2A
SCHEMBL3917146 0.87 HSD17B1 (0.45) BRD4LMNABRPF1NR1I2MAPT
SCHEMBL3907941 0.83 PKM (0.48) LMNABRPF1NR1I2MAPTTP53
SCHEMBL1811589 0.82 TRIM24 (0.50) BRD4BRPF1NR1I2MAPTTP53
SCHEMBL3908715 0.82 ITGA1 (0.51) BRD4LMNANR1I2MAPTKMT2A
SCHEMBL3903016 0.78 NR1I2 (0.48) BRD4LMNANR1I2MAPTKMT2A
SCHEMBL1811576 0.78 HSD17B1 (0.47) BRD4LMNANR1I2MAPTTP53
SCHEMBL3916206 0.77 BRD4 (0.52) BRD4LMNANR1I2MAPTTP53
SCHEMBL1843607 0.74 PKM (0.50) LMNANR1I2MAPTTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 BRD4 2606/4885LMNA 3419/4885BRPF1 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.